Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Solid Tumors with Brain Metastases
NCT05064280Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2022
- Primary completion
- Feb 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and lenvatinib in brain metastasis (BM), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 1 more (3 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Intracranial Objective Response Rate assessed by modified RECIST v1.1 at 1 year. Started Jan 2022; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
brain metastasis (BM)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05064280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064280.